A Oliff
Overview
Explore the profile of A Oliff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dutta G, Silver D, Oliff A, Harrison A
Case Rep Urol
. 2012 May;
2011:832673.
PMID: 22606626
Renal cell carcinoma (RCC) and urothelial carcinoma of the upper urinary tract are not uncommon urological malignancies. Their simultaneous occurrence in a patient is, however, extraordinarily rare. We report the...
2.
Sepp-Lorenzino L, Tjaden G, Moasser M, Timaul N, Ma Z, Kohl N, et al.
Prostate Cancer Prostatic Dis
. 2002 Dec;
4(1):33-43.
PMID: 12497061
The effects of farnesyl:protein transferase inhibitors (FTIs) were evaluated against hormone-dependent and hormone-independent prostate cancer cell lines harboring mutant and wild type Ras. The combinations of the FTI with hormones...
3.
Garsky V, Lumma P, Feng D, Wai J, Ramjit H, Sardana M, et al.
J Med Chem
. 2001 Nov;
44(24):4216-24.
PMID: 11708923
Doxorubicin (Dox) can provide some stabilization in prostate cancer; however, its use is limited because of systemic toxicities, primarily cardiotoxicity and immunosuppression. The administration of a prodrug of doxorubicin, designed...
4.
Huang P, Oliff A
Trends Cell Biol
. 2001 Aug;
11(8):343-8.
PMID: 11489640
Genetic instability contributes to the origin of cancer as well as to the ability of cancer cells to become resistant to various therapies. Because of this, cytotoxic rather than cytostatic...
5.
Wong B, Jones R, Garsky V, Feng D, Oliff A, Chiba M, et al.
Drug Metab Dispos
. 2001 Feb;
29(3):313-8.
PMID: 11181501
Tumor-selective delivery of doxorubicin by a prostate-specific antigen (PSA)-targeted peptide conjugate prodrug of doxorubicin was demonstrated in a nude mouse xenograft model of human prostate cancer. The prodrug (referred to...
6.
Prendergast G, Oliff A
Semin Cancer Biol
. 2001 Feb;
10(6):443-52.
PMID: 11170866
Farnesyltransferase (FTase) inhibitors are among the current wave of molecularly targeted anti-cancer agents being used to attack malignancy in a rational manner. A large body of preclinical data indicates that...
7.
Huang P, Oliff A
Curr Opin Genet Dev
. 2001 Feb;
11(1):104-10.
PMID: 11163159
Genetic changes in cell-cycle, apoptotic, and survival pathways cause tumorigenesis, leading to significant phenotypic changes in transformed cells. These changes in the tumor environment - elevated expression of surface proteases,...
8.
Garsky V, Wong B, Feng D, Bolyar T, Haskell K, Kiefer D, et al.
Nat Med
. 2000 Nov;
6(11):1248-52.
PMID: 11062536
We covalently linked doxorubicin with a peptide that is hydrolyzable by prostate-specific antigen. In the presence of prostate tumor cells secreting prostate-specific antigen, the peptide moiety of this conjugate, L-377,202,...
9.
Cohen-Jonathan E, Muschel R, McKenna W, Evans S, Cerniglia G, Mick R, et al.
Radiat Res
. 2000 Aug;
154(2):125-32.
PMID: 10931682
Successful radiosensitization requires that tumor cells become more radiosensitive without causing an equivalent reduction in the survival of cells of the surrounding normal tissues. Since tumor cell radiosensitivity can be...
10.
Omer C, Chen Z, Diehl R, Conner M, Chen H, Trumbauer M, et al.
Cancer Res
. 2000 May;
60(10):2680-8.
PMID: 10825141
For Ras oncoproteins to transform mammalian cells, they must be posttranslationally modified with a farnesyl group in a reaction catalyzed by the enzyme farnesyl:protein transferase (FPTase). Inhibitors of FPTase have...